Company News | News List - Fluoropharm

Company News | News List

Targeting specific DNA of Plasmodium may be effective in treating human malaria infection

Targeting specific DNA of Plasmodium may be effective in treating human malaria infection

Targeting a parasite's DNA could be a more effective way to combat malaria, new research from th

READ MORE 2022-07-28

Vijoice is the first FDA-approved PRS treatment

Vijoice is the first FDA-approved PRS treatment

2022.04.06, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelera

READ MORE 2022-07-06

Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib

Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03

READ MORE 2022-06-13

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadel

READ MORE 2022-05-13

Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib

Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib

Recently, Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension t

READ MORE 2022-05-12

ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

ViiV Healthcare announced that the US Food and Drug Administration (FDA) approvedApretude, the first

READ MORE 2021-12-22

FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma

FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S.

READ MORE 2021-09-07

Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU

Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU

Berlin, Germany, July 21, 2021– The European Commission has granted marketing authorization in the E

READ MORE 2021-07-26

Tagrisso approved in China in early lung cancer

AstraZeneca'sTagrisso(osimertinib) has been approved in China for the adjuvant treatment of pati

READ MORE 2021-04-15

Progress in the development of new and efficient diabetes treatment drugs

Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy

READ MORE 2021-01-19

Copyright © 2010-2025 Fluoropharm Co.,Ltd. All rights reserved.

浙ICP备2023037538号-1